Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
24.98 EUR | -0.64% | -1.19% | -32.47% |
May. 31 | Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment | MT |
May. 31 | Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.47% | 1.8B | |
+57.32% | 59.34B | |
+43.06% | 40.24B | |
-4.78% | 39.88B | |
-5.56% | 28.55B | |
+16.58% | 27.26B | |
-20.68% | 19.23B | |
+32.20% | 12.61B | |
+3.24% | 12.49B | |
+26.14% | 12.28B |
- Stock Market
- Equities
- GLPG Stock
- News Galapagos NV
- Morgan Stanley Adjusts Galapagos' Price Target to $40 From $42, Keeps Equalweight Rating